We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From Apr 2019 to Apr 2024
AstraZeneca spends a few million dollars a year on its Emerging Innovations Unit, with other research funding coming from outside sources. "AstraZeneca Gives Rejected Drugs a Second Life," at 1100 GMT, incorrectly stated that the company spent tens of millions of dollars a year on the unit in the 14th paragraph. Also, AstraZeneca shelved a schizophrenia drug candidate because it didn't work in schizophrenia. An earlier version of this article incorrectly stated it was shelved because of its hormonal side effects in the 17th paragraph.
(END) Dow Jones Newswires
March 13, 2017 10:51 ET (14:51 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
